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Abstract 
The complementary nature of positron emission tomography (PET) and near-infrared 
fluorescence (NIRF) imaging makes the development of strategies for the multimodal PET/NIRF 
imaging of cancer a very enticing prospect. Indeed, in the context of colorectal cancer, a single 
multimodal PET/NIRF imaging agent could be used to stage the disease, identify candidates for 
surgical intervention, and facilitate the image-guided resection of the disease. While antibodies 
have proven to be highly effective vectors for the delivery of radioisotopes and fluorophores to 
malignant tissues, the use of radioimmunoconjugates labeled with long-lived nuclides such as 89Zr 
poses two important clinical complications: high radiation doses to the patient and the need for 
significant lag time between imaging and surgery. In vivo pretargeting strategies that decouple the 
targeting vector from the radioactivity at the time of injection have the potential to circumvent 
these issues by facilitating the use of positron-emitting radioisotopes with far shorter half-lives. 
Here, we report the synthesis, characterization, and in vivo validation of a pretargeted strategy for 
the multimodal PET and NIRF imaging of colorectal carcinoma. This approach is based on the rapid 
and bioorthogonal ligation between a trans-cyclooctene- and fluorophore-bearing 
immunoconjugate of the huA33 antibody (huA33-Dye800-TCO) and a 64Cu-labeled tetrazine 
radioligand (64Cu-Tz-SarAr). In vivo imaging experiments in mice bearing A33 antigen-expressing 
SW1222 colorectal cancer xenografts clearly demonstrate that this approach enables the 
non-invasive visualization of tumors and the image-guided resection of malignant tissue, all at only 
a fraction of the radiation dose created by a directly labeled radioimmunoconjugate. Additional in 
vivo experiments in peritoneal and patient-derived xenograft models of colorectal carcinoma 
reinforce the efficacy of this methodology and underscore its potential as an innovative and useful 
clinical tool. 
Key words: PET, fluorescence imaging, multimodal imaging, colorectal carcinoma, pretargeting, bioorthogonal 
chemistry, site-specific bioconjugation. 
Introduction 
Colorectal cancer is the second most common 
malignancy in women, the third most common 
malignancy in men, and the fourth most common 
cause of cancer mortality worldwide.1,2 In the US, the 
situation is even more dire, as this insidious disease is 
the third most common cause of cancer and the 
second most common cause of cancer mortality.3 The 
surgical excision of the affected segments of the colon 
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has emerged as a standard of care for the treatment of 
colorectal cancer.4 However, surgery is only effective 
in patients with localized disease. Patients with 
metastatic disease — who account for up to 25% of 
initial diagnoses — are not eligible for resection.5,6 Not 
surprisingly, attempts at surgical intervention in these 
patients can actually be counter-productive, primarily 
because surgery can delay the start of chemotherapy.7 
Clearly, the accurate initial staging of colorectal 
carcinoma using rapid and non-invasive methods is 
absolutely essential to planning effective treatment 
regimens. 
Over the past two decades, two imaging 
modalities have emerged that have begun to have a 
transformational impact on the clinical management 
of cancer. First, positron emission tomography (PET) 
— and immunoPET in particular — has become 
established as a powerful tool for the sensitive and 
specific functional imaging of cancer.8 Second, 
near-infrared fluorescence (NIRF) imaging has proven 
to be a very promising technique for the 
image-guided resection of tumor tissue, as it 
facilitates the real-time, high-resolution delineation of 
tumor margins during surgery.9,10 The 
complementary nature of these two modalities has led 
to a number of preclinical investigations focused on 
the creation of immunoconjugates for multimodal 
PET and NIRF imaging.11–18 The hypothesis 
underpinning this work is that a single multimodal 
PET/NIRF imaging agent could perform two valuable 
functions. Via PET, the imaging agent could help 
clinicians non-invasively determine the extent of 
disease and, as a result, whether a given patient is a 
candidate for surgery. Then, if surgery does occur, the 
same probe could be used for intraoperative NIRF 
imaging, thereby aiding surgeons in the delineation of 
tumor margins and facilitating the more thorough 
resection of the disease. Hong et al., for example, have 
recently developed a 89Zr- and IRDye800CW-labeled 
immunoconjugate of the CD105-targeting antibody 
TCR105 for the multimodal PET and NIRF imaging of 
murine models of metastatic breast cancer.15 
Despite the immense potential of multimodal 
PET/NIRF immunoconjugates, two principal 
obstacles stand in the way of their widespread clinical 
implementation. Both of these issues stem from the 
isotopes traditionally used to radiolabel antibodies. 
The multi-day circulation times of antibodies means 
that to be effective imaging agents, they must be 
labeled with radioisotopes with multi-day physical 
half-lives such as 89Zr (t1/2 ~ 3.2 days) or 124I (t1/2 ~ 4.2 
days). The use of these long-lived isotopes creates an 
important clinical complication: high radiation doses 
to healthy organs. In the context of multimodal 
PET/NIRF imaging, a second issue arises. In order to 
eschew operations on radioactive patients, multiple 
days (or even weeks) would be required between 
imaging and surgery to allow the radioisotope to 
decay. Critically, it is possible that the cancer can 
spread during this delay, rendering the initial staging 
scans obsolete and casting the feasibility of surgery 
into doubt. The latter point is particularly germane in 
the context of malignancies with fast doubling rates, 
such as colorectal and ovarian cancer. 
In vivo pretargeting approaches could 
circumvent these issues by harnessing the high 
specificity and affinity of radioimmunoconjugates 
while simultaneously avoiding their sluggish 
pharmacokinetics and high background doses.19 To 
achieve this, pretargeting strategies decouple the 
antibody from the radioisotope at the time of injection 
and combine these two components within the body. 
In essence, the radioimmunoconjugate is synthesized 
at the tumor itself. In vivo radiolabeling strategies offer 
clear advantages over conventional radioimmuno-
conjugates, as they facilitate tumor imaging at earlier 
time points, enable the use of shorter-lived 
radionuclides [e.g.64Cu (t1/2 = 12.7 h) and 68Ga (t1/2 = 68 
min) rather than 89Zr or 124I], and produce significant 
reductions in radiation dose rates to patients. In the 
past, several strategies — ranging from bispecific 
antibodies to systems based on the affinity between 
streptavidin and biotin — have been developed to 
facilitate the in vivo ligation of antibodies and 
radioligands.19 However, these approaches have 
suffered from several drawbacks, including the 
immunogenicity of streptavidin-based immune-
conjugates and the complexity and lack of versatility 
of bispecific antibodies. 
Over the past five years, our laboratories and a 
handful of others have pioneered in vivo pretargeting 
strategies based on the extraordinarily rapid and 
bioorthogonal inverse electron demand Diels-Alder 
(IEDDA) reaction between tetrazine (Tz) and 
trans-cyclooctene (TCO) (Figure 1A).20–27 Generally 
speaking, this approach employs two components — 
a tetrazine-based radioligand and a TCO-bearing 
immunoconjugate — and four facile steps: (1) the 
injection of the mAb-TCO conjugate; (2) a localization 
time period during which the antibody accumulates 
in the tumor and clears from the blood; (3) the 
injection of the radiolabeled tetrazine; and (4) the in 
vivo click ligation of the two components followed by 
the rapid excretion of excess radioligand.23,28 
Preclinical PET imaging studies in murine models of 
both colorectal and pancreatic cancer have clearly 
shown that this pretargeting methodology delivers 
high concentrations of radioactivity to tumor tissue at 
much earlier time points than directly radiolabeled 
antibodies, produces high tumor-to-background 
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activity concentration ratios, and significantly reduces 
the overall radiation burden to the patient compared 
to analogous traditional radioimmunoconjugates.28,29 
We contend that a pretargeted approach to 
multimodal PET/NIRF imaging would solve both of 
the issues that threaten to limit traditional multimodal 
radioimmunoconjugates: it would (1) dramatically 
lower the radiation dose to healthy tissues and (2) 
significantly reduce the requisite lag time between 
PET imaging and surgical intervention. To this end, 
we have developed a pretargeted multimodal 
PET/NIRF imaging agent based on an 
immunoconjugate of the huA33 antibody labeled with 
both a near-IR fluorophore (Dye800) and TCO 
(huA33-Dye800-TCO) and a 64Cu-labeled tetrazine 
radioligand (64Cu-Tz-SarAr) (Figs. 1B and 2). We 
report that this approach enables the rapid and 
non-invasive visualization of tumor tissue with 
excellent tumor-to-background activity concentration 
ratios. Furthermore, simulated tumor resections using 
a NIRF camera clearly demonstrate that this approach 
could be a very powerful tool for the real-time 
delineation of malignant tissue during image-guided 
surgery. Ultimately, we believe that this 64Cu-based 
system offers a dramatic improvement over 
multimodal PET/NIRF radioimmunoconjugates 
synthesized using traditional, direct-labeling 
methodologies.  
 
 
Figure 1. (A) The inverse electron demand Diels-Alder reaction between tetrazine and trans-cyclooctene; (B) 64Cu-Tz-SarAr. 
 
 
Figure 2. Biochemical (A) and temporal (B) schematics of the bioorthogonal pretargeting strategy for multimodal PET and NIRF imaging. 
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Materials and Methods 
A detailed description of experimental 
procedures — including synthetic protocols, biocon-
jugation techniques, radiolabeling methodologies, 
and the design and execution of in vitro and in vivo 
experiments — can be found in the Supplementary 
Materials. 
Results and Discussion 
Design, Synthesis, and Characterization 
The foundation of our multimodal imaging 
system lies in the pretargeted approach to the PET 
imaging of colorectal cancer that we have previously 
reported.27,28 This approach pairs a 64Cu-sarco-
phagine-based tetrazine radioligand (64Cu-Tz-SarAr) 
with a TCO-labeled immunoconjugate of the huA33 
antibody (huA33-TCO).28 This antibody has 
previously been shown to be an excellent targeting 
vector for the A33 antigen, a glycoprotein biomarker 
that is over-expressed by 95% of colorectal 
carcinomas.30–34 Critically, in vitro studies have shown 
that the huA33-A33 antigen complex is not 
internalized and persists on the surface of the cell for 
days after its formation, making this antibody-antigen 
pair an ideal platform for in vivo pretargeting.35 The 
near-infrared dye IRDye®800CW (Dye800) was 
selected as the fluorescent reporter for this system for 
three reasons: it emits tissue-penetrating 789 nm light, 
it has been approved for clinical applications, and it 
has been successfully employed in several 
dual-labeled PET/NIRF immunoconjugates.12,14–17 
Two different bioconjugation approaches were 
used to append the TCO and Dye800 moieties to the 
antibody in order to achieve maximum 
functionalization with minimal impairment of the 
antibody’s functionality. The NIR fluorophore was 
attached first. To this end, we employed a 
chemoenzymatic strategy that site-specifically 
appends cargoes to the biantennary heavy chain 
glycans located on the CH2 domains of the antibody’s 
Fc region.36 This methodology is designed to mitigate 
the adverse effects that the random attachment of 
cargoes can have on the immunoreactivity and 
pharmacokinetic profile of immunoconjugates. 
Indeed, a number of different studies have 
demonstrated that site-specifically labeled 
immunoconjugates are not only more homogenous 
and better-defined than their randomly labeled 
cousins but also often boast superior in vivo 
performance.36–39 Along these lines, we have 
previously applied this bioconjugation strategy to the 
development of huA33-based multimodal imaging 
agents; however, in this case, we observed that the 
site-specifically modified constructs possess almost 
identical — if not slightly more favorable — in vivo 
behavior compared to their traditionally synthesized 
cousins.18 This result is almost certainly a consequence 
of the well-optimized and robust nature of the huA33 
antibody. Nonetheless, for the investigation at hand, 
we chose to employ this site-specific approach in 
order to guarantee that we have minimized the 
influence of the bulky and hydrophobic Dye800 on 
the in vitro and in vivo performance of the 
TCO-decorated antibody.  
This site-specific bioconjugation strategy 
involves three steps: (1) the removal of the terminal 
galactose residues of the glycans using 
β-1,4-galactosidase; (2) the attachment of 
azide-modified monosaccharides (GalNAz) to the 
glycans using Gal-T1(Y289L), a promiscuous 
galactosyltransferase; and (3) the ligation of 
dibenzocyclooctyne-bearing derivatives of Dye800 
(DIBO-Dye800) to the azide-terminated sugar chains 
via the strain-promoted azide-alkyne click (SPAAC) 
ligation (Fig. 3).40–43 Interestingly, UV-Vis 
measurements revealed that the huA33-Dye800 
immunoconjugate had a degree of labeling of 1.1 ± 0.1 
Dye800/mAb. This ratio is admittedly lower than the 
theoretical maximum, given that the biantennary 
structure of the glycans means that a degree of 
labeling of 4 is possible. Indeed, degrees of labeling 
closer to 4 have been obtained using chelators (e.g. 
DIBO-DFO) and other, shorter-wavelength dyes (e.g. 
DIBO-AlexaFluor® 488).18,44 However, this lower 
value is consistent with results previously obtained 
using a DIBO construct labeled with another bulky 
and hydrophobic NIRF dye, AlexaFluorTM 680 
(AF680): 1.6 ± 0.2 AF680/mAb.18 Efforts at 
understanding this phenomenon are currently 
underway, though at present we hypothesize that this 
reduction in reaction efficiency may best be explained 
by the steric hindrance produced by the introduction 
of a bulky and hydrophobic fluorophore with a large 
hydrodynamic radius.  
The site specificity of this bioconjugation 
procedure was demonstrated via denaturing gel 
electrophoresis experiments performed on 
huA33-Dye800 and huA33-Dye800-TCO (vide infra) 
before and after treatment with PNGaseF, an 
endoglycosidase known to efficiently cleave the 
N-linked oligosaccharides from the CH2 domains. 
Importantly, in the lanes containing the untreated 
immunoconjugates, fluorescence signal can only be 
observed in the band representing the heavy chain. 
Even more convincingly, a complete loss of 
fluorescence can be observed for the heavy chain 
bands of the PNGaseF-treated immunoconjugates 
(Fig. S1 and S2). 
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Figure 3. Schematic of the synthesis of huA33-Dye800-TCO. 
 
Figure 4. Planar (left) and maximum intensity projection (MIP; right) pretargeted PET images of a nude mouse bearing subcutaneous SW1222 xenograft on the left 
shoulder. The mouse was injected with huA33-Dye800-TCO (100 μg; 0.66 nmol), followed 48 h later by 64Cu-Tz-SarAr (350-400 μCi; 0.66-0.77 nmol). The coronal 
slices intersect the center of the tumors. 
 
Next, in line with previously reported 
procedures, TCO moieties were grafted to the 
huA33-Dye800 immunoconjugate through the 
coupling of NHS ester-bearing TCOs to the lysine 
residues of the antibody. The site-specific conjugation 
of TCO via a dual labeling approach similar to that 
which we have recently published was considered.18,27 
However, we did not want the degree of labeling of 
TCO to be impacted by the presence of Dye800 or 
limited by the availability of the four azide-modified 
monosaccharides. Ultimately, the conjugation of 
TCO-NHS to huA33-TCO yielded the completed 
huA33-Dye800-TCO conjugate after purification via 
size exclusion chromatography.23 Quantification of 
the number of active TCO moieties attached to the 
antibody was achieved via UV-Vis spectrophotometry 
following the reaction of huA33-Dye800-TCO with a 
tetrazine-bearing fluorescent probe: Tz-PEG7-AF488. 
A degree of labeling of 3.0 ± 0.5 active TCOs/mAb 
was obtained. Finally, in order to assess the impact of 
the two bioconjugations on the affinity of the antibody 
for its target, an antigen binding assay was performed 
using A33 antigen-expressing SW1222 human 
colorectal carcinoma cells. The 64Cu-labeled 
radioimmunoconjugate — obtained via the ex vivo 
reaction of huA33-Dye800-TCO and 64Cu-Tz-SarAr 
and subsequent size exclusion chromatography — 
possessed an immunoreactive fraction of 0.90 ± 0.03. 
In Vivo PET Imaging and Biodistribution 
The in vivo performance of pretargeted imaging 
with huA33-Dye800-TCO and 64Cu-Tz-SarAr was next 
evaluated in mice bearing subcutaneous A33 
antigen-expressing SW1222 colorectal carcinoma 
xenografts. To this end, huA33-Dye800-TCO (100 µg; 
0.66 nmol) was administered intravenously to the 
tumor-bearing mice followed — after a 48 hour 
pretargeting interval — by 64Cu-Tz-SarAr (350-400 
µCi; 0.66-0.77 nmol). Previous work by our 
laboratories has illustrated that this 48-hour interval 
produces high tumor-to-background activity 
concentration ratios as well as high absolute activity 
concentrations in the tumor tissue itself.28 
PET images were collected 4, 12, and 24 h after 
the administration of the radioligand (Fig. 4, Fig. S3). 
The images acquired at the earliest time point clearly 
illustrate that this system is capable of the rapid and 
high contrast visualization of tumor tissue. The 
images improve with time, with the tumor far and 
away the organ with the highest activity 
concentration by 12 and 24 h post-injection. 
Biodistribution experiments mirrored the 
observations made during PET imaging (Table 1). At 1 
h post-injection, the activity concentration in the 
tumor is 5.6 ± 1.4 %ID/g, a value which grows to 12.8 
± 2.2 %ID/g by 24 h. Over the same time period, the 
activity in the blood drops from 6.9 ± 2.1 %ID/g to 2.6 
± 0.6 %ID/g. By the later time points, all healthy 
organs except for the kidneys have activity 
concentrations below — and often well below — 1.9 
%ID/g. The kidneys were the non-target organs with 
the highest activity concentrations (3.9 ± 0.6 %ID/g 
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and 2.1 ± 0.2 %ID/g at 1 and 24 h, respectively), a 
result of the renal elimination of excess, ‘unclicked’ 
64Cu-Tz-SarAr radioligand. 
 
Table 1. Biodistribution data for in vivo pretargeting with 
huA33-Dye800-TCO and 64Cu-Tz-SarAr. 
 1 h 4 h 12 h 24 h 
Blood  6.9 ± 2.1a 5.5 ± 0.9 5.3 ± 0.5 2.6 ± 0.6 
Tumor 5.6 ± 1.4 8.0 ± 1.5 15.6 ± 1.7 12.8 ± 2.2 
Heart 2.7 ± 0.8 2.2 ± 0.5 2.1 ± 0.3 1.1 ± 0.2 
Lung 3.4 ± 1.5 3.7 ± 0.7 3.3 ± 0.2 1.6 ± 0.3 
Liver 2.7 ± 0.8 2.6 ± 0.4 2.2 ± 0.2 1.9 ± 0.4 
Spleen 1.6 ± 0.7 1.3 ± 0.4 1.3 ± 0.2 1.2 ± 0.3 
Stomach 0.6 ± 0.2 0.4 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 
Small Intestine 1.0 ± 0.4 0.6 ± 0.1 0.6 ± 0.1 0.5 ± 0.1 
Large Intestine 0.5 ± 0.2 0.8 ± 0.2 0.4 ± 0.1 0.4 ± 0.2 
Kidney 3.9 ± 0.6 3.2 ± 0.1 2.9± 0.3 2.1 ± 0.2 
Muscle 0.5 ± 0.3 0.5 ± 0.1 0.6 ± 0.1 0.3 ± 0.1 
Bone 0.8 ± 0.3 0.6 ± 0.1 0.8 ± 0.2 0.6 ± 0.1 
aValues are %ID/g ± SD. Mice (n = 4) bearing subcutaneous SW1222 xenografts 
were administered huA33-Dye800-TCO (100 µg; 0.66 nmol) via tail vein injection. 
After 48 h, the same mice were administered 64Cu-Tz-SarAr (300-400 µCi; 0.66-0.77 
nmol), also via tail vein injection. Stomach, small intestine, and large intestine 
values include contents. 
 
 
These biodistribution results underscore some 
intriguing differences between this multimodal 
pretargeting system and our previously published 
PET-only pretargeting strategy based on huA33-TCO 
and 64Cu-Tz-SarAr.28 In experiments using a 48 h 
pretargeting interval, the latter system yielded a 
tumoral activity concentration of 4.5 ± 0.4 %ID/g at 1 
h post-injection, a value which did not appreciably 
change over the course of 24 h (4.9 ± 0.7 %ID/g at 24 
h). This strongly suggests that the vast majority of in 
vivo click ligations occurred at the tumor rather than 
in the blood. In this multimodal pretargeting system, 
high activity concentrations (5.6 ± 1.4 %ID/g) can be 
observed in the tumor at 1 h post-injection, which is 
also indicative of significant click ligations at the 
tumor site. However, in this case, the activity 
concentrations in the tumor increase over the course of 
the experiment, ultimately reaching 12.8 ± 2.2 %ID/g 
at 24 h. The activity concentrations in the blood are 
also higher for the multimodal approach than the 
PET-only strategy: at 4 h post-injection, for example, 
the former produces a blood activity concentration of 
5.5 ± 0.8 %ID/g compared to a value of 1.8 ± 0.3 
%ID/g for the latter. These data suggest that in the 
multimodal system, an appreciable amount of 
‘in-blood’ ligations are occurring in addition to the 
‘on-tumor’ reactions. The most likely explanation for 
this phenomenon is that the addition of the 
hydrophobic and bulky NIR fluorophore alters the 
pharmacokinetics of the immunoconjugate, giving the 
huA33-Dye800-TCO construct a longer blood half-life 
than its singly modified huA33-TCO cousin. 
Ultimately, this issue is not a problem, per se. 
However, it does suggest that longer pretargeting 
intervals may be necessary to maximize the 
dosimetric benefits of this imaging system. Indeed, a 
pilot imaging study using a 96 h pretargeting interval 
hints that this is the case: the activity concentrations in 
the blood are lower throughout the experiment, and 
the activity concentration in the tumor are very 
similar at 4 and 24 h post-injection (Fig. S4). In the 
end, though, it is important to note that even with 
these slightly elevated activity concentrations in the 
blood, this multimodal pretargeting strategy 
produces promising tumor-to-non-target tissue 
activity concentration ratios. For example, at 24 h 
post-injection, the tumor-to-blood and 
tumor-to-muscle activity concentration ratios are ~5 
and ~42, respectively (Table S1). Even more 
importantly, the tumor-to-organ activity 
concentration ratios for the site of primary tumors (the 
large intestine) and the most likely site of metastatic 
disease (the liver) are also high: ~33 and ~7, 
respectively. 
In Vivo NIRF Imaging  
 The PET and biodistribution results strongly 
suggest that this system could be highly effective for 
the image-guided resection of tumor tissue. To 
explore this possibility, NIRF imaging (λex = 745 nm; 
λem = 820 nm) was performed on the mice of the PET 
imaging cohort immediately before the 
administration of the 64Cu-Tz-SarAr radioligand as 
well as 24 and 48 h thereafter (and thus 48, 72, and 96 
h after the injection of huA33-Dye800-TCO; see Fig. 2B 
for a temporal scheme). The in vivo fluorescence images 
clearly illustrate the specific localization of 
huA33-Dye800-TCO to the subcutaneous xenografts 
(Fig. S5 and Fig. 5A). Simulated tumor resections 
further illustrate the potential of this approach for 
image-guided surgery. After the removal of the skin 
above the fluorescent area, the NIRF signal increases, 
and the tumor margins appear clearly, facilitating the 
excision of all the tumor tissue (Fig. 5B). NIRF imaging 
of the mice after the removal of the tumor clearly 
shows that there is no more fluorescent tissue in the 
surgical cavity, confirming the complete resection of 
the lesion. Finally, the tumors and a selection of 8 
organs were excised and compared via ex vivo NIRF 
imaging (Fig. 5C). These images and the 
accompanying radiant efficiency values reinforce the 
specific and selective targeting of this system (Fig. 5D; 
for more examples, see Fig. S6-S7). The tumor tissue has 
a radiant efficiency of 1393.0 ± 46.0 (units = 106 
photons⋅sec-1⋅cm-2⋅sr-1/µW⋅cm-2), a value over an 
order of magnitude greater than that of the heart (32.5 
± 3.4), lungs (37.0 ± 0.7), liver (107.5 ± 14.0), small 
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intestine (54.5 ± 18.4), large intestine (35.9 ± 5.3), and 
kidneys (52.0 ± 2.6) (see Table S2). As a result, the 
tumor-to-liver radiant efficiency ratio is 13, and the 
corresponding ratios for all of the other healthy 
organs were >22, including a particularly promising 
tumor-to-large intestine radiant efficiency ratio of >38. 
Histology and Autoradiography 
The subcutaneous xenografts from the mice of 
the PET and NIRF imaging cohort were excised in 
order to further study the microscopic distribution of 
the radioligand and fluorophore (Fig. 6). Staining for 
the A33 glycoprotein reveals a clear co-localization 
between the expression of the A33 antigen and the 
fluorescence of Dye800, which could only be detected 
in areas corresponding to tumor cells and not 
vasculature, necrosis, or stroma. Most importantly, 
autoradiographical analysis reveals that the 
radiotracer can only be observed in areas where the 
Dye800-fluorescence signal is also detected, providing 
further evidence for the in vivo formation of the 
64Cu-SarAr-huA33-Dye800 radioimmunoconjugate. 
In Vivo Multimodal Imaging in Alternative 
Murine Models of Colorectal Cancer 
In order to more fully characterize the in vivo 
performance of this multimodal imaging system, we 
also performed experiments using peritoneal and 
patient-derived colorectal cancer xenografts. With 
regard to the former, SW1222 human colorectal 
carcinoma cells were injected into the peritoneum of 
athymic nude mice. After 3-4 weeks, pretargeted PET 
imaging with huA33-Dye800-TCO and 64Cu-Tz-SarAr 
clearly revealed small peritoneal tumors while 
producing minimal activity concentrations in the 
surrounding non-target tissues (Fig. 7A). Subsequent 
NIRF imaging confirmed the presence of these lesions 
and enabled the image-guided removal of the tumor 
tissue (Fig. 7C). Interestingly, in one mouse, the NIRF 
imaging revealed the presence of extremely small (<1 
mm) colorectal metastases that had escaped detection 
via PET, mostly likely due to the higher resolution of 
NIRF imaging compared to microPET imaging. 
 
 
 
Figure 5. (A) Near-infrared fluorescence images (λex = 745 nm; λem = 820 nm) of a mouse bearing a subcutaneous SW1222 xenograft on the left shoulder acquired 
2 h after the injection of huA33-Dye800-TCO and 48 h after the subsequent administration of 64Cu-Tz-SarAr. (B) Simulated image-guided resection of the tumor 96 
h after the injection of huA33-Dye800-TCO. From left to right: intact mouse, mouse after removal of the skin (blue arrow) covering the tumor, and mouse after 
excision of the tumor (white arrow). (C) Fluorescence imaging of a selection of organs (1: tumor, 2: heart, 3: lungs, 4: liver, 5: spleen, 6: stomach, 7: small intestine, 
8: large intestine, 9: kidneys). (D) Ex vivo radiant efficiencies (in 106 photons⋅sec-1⋅cm-2⋅sr1/μW⋅cm-2) of a selection of organs. 
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Figure 6. Tumor slices excised from a mouse 72 hours after injection of huA33-Dye800-TCO (100 µg; 0.66 nmol) and 24 h after administration of 64Cu-Tz-SarAr 
(350-400 μCi; 0.66-0.77 nmol). Upper section: (A) Hematoxylin and eosin staining, (B) immunofluorescence staining for the A33 antigen, (C) confocal fluorescence 
of the Dye800 signal, and (D) digital autoradiography. Lower section: magnified areas of the tumor slices corresponding to the white boxes in the top left panel. 
 
 
Figure 7. Planar (A) and maximum intensity projection (MIP; B) pretargeted PET images of a nude mouse bearing peritoneal SW1222 tumors (white arrows). The 
mouse was injected with huA33-Dye800-TCO (100 µg; 0.66 nmol), followed 48 h later with 64Cu-Tz-SarAr (350-400 μCi; 0.66-0.77 nmol). The coronal slice 
intersects the center of the tumors. (C) Simulated NIRF-guided resection of the tumor 96 h after the injection of huA33-Dye800-TCO (and thus 48 h after the 
injection of 64Cu-Tz-SarAr; λex = 745 nm and λem = 820 nm). From left to right: NIRF image of the tumors (black arrows) under the skin; NIRF image of the mouse 
after the excision of the two tumor masses; inset image of the colon, revealing small tumor lesions visible only via NIRF imaging. 
 
Finally, pretargeted PET/NIRF imaging of mice 
bearing patient-derived colorectal cancer xenografts 
(PDXs) produced similarly promising results (Fig. 8). 
Indeed, both the PET and NIRF image contrast 
between the malignant tissue and healthy organs 
proved to be more than sufficient for the non-invasive 
visualization of the tumor and its efficient 
image-guided resection. Interestingly, however, the 
tumor-to-blood activity concentration ratios seemed 
to be quite a bit higher in these experiments than in 
those using SW1222-based xenografts. The most likely 
explanation for this phenomenon is that while the 
same amount of Dye800-huA33-TCO (100 µg) was 
injected for the imaging experiments in both models, 
the PDXs do not express the A33 antigen at levels 
comparable to their SW1222 xenograft counterparts. 
This would naturally result in decreased amounts of 
Dye800-huA33-TCO in the tumor, increased amounts 
of Dye800-huA33-TCO in the blood, and a higher 
proportion of in vivo click ligations with 
64Cu-Tz-SarAr that occurs in the blood. 
Dosimetry 
Finally, the biodistribution data from the 
experiments using subcutaneous SW1222 xenografts 
were used to perform dosimetry calculations to probe 
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the dosimetric benefits of pretargeting with 
huA33-Dye800-TCO and 64Cu-Tz-SarAr (see Table S3). 
These calculations reveal that the total effective dose 
for this multimodal pretargeting strategy is 0.021 
mSv/MBq, an over 20-fold reduction compared to 
that created by the most clinically relevant alternative: 
huA33 directly labeled with 89Zr (89Zr-DFO-huA33; 
0.416 mSv/MBq).23 This dosimetric advantage grows 
when considering particularly radiosensitive organs 
such as the red marrow (40-fold difference), 
osteogenic cells (30-fold difference), and kidneys 
(33-fold difference). Admittedly — and not 
surprisingly, given our previous discussion of the 
biodistribution data — this multimodal strategy has a 
slightly higher effective dose (0.021 mSv/MBq) than 
our PET-only system (0.012 mSv/MBq), most likely 
due to the increased activity concentrations in the 
blood. 
Conclusion 
 In the preceding pages, we have presented the 
development and in vivo validation of a pretargeted 
approach to the multimodal PET/NIRF imaging of 
colorectal carcinoma. In subcutaneous, peritoneal, 
and patient-derived xenograft models, we have 
shown that this technology enables both the 
non-invasive visualization of malignant lesions and 
the NIRF-guided excision of tumor tissue. As a result, 
we contend that this technology could offer an 
effective alternative to multimodal imaging with 
directly radiolabeled antibodies that lowers the total 
effective radiation dose to patients and reduces the lag 
time between PET imaging and surgery. Moving 
forward, we plan on pursuing three different avenues 
for the optimization of this approach: (1) the use of 
longer pretargeting intervals (e.g. 96 or 120 h) that will 
reduce the amount of immunoconjugate remaining in 
the blood at the injection of the radioligand; (2) the 
use of tetrazine-bearing clearing agents to remove 
residual immunoconjugate in the blood after the 
pretargeting interval; and (3) the use of radioligands 
bearing even shorter-lived radioisotopes such as 68Ga 
(t1/2 = 68 min) and 18F (t1/2 = 110 min).21,26,45,46 We 
believe that each of these steps could improve upon 
the already significant advantages that this system 
provides over imaging with traditional 
radioimmunoconjugates. Indeed, all three alterations 
could lead to additional reductions in the effective 
radiation dose created by this system, and the third 
could further reduce the necessary interval between 
 
 
Figure 8. Planar (A) and maximum intensity projection (MIP; B) pretargeted PET images of a nude mouse bearing a patient-derived colorectal carcinoma xenograft 
(T: tumor, L: liver, H: heart). The mouse was injected with huA33-Dye800-TCO (100 µg; 0.66 nmol), followed 48 h later with 64Cu-Tz-SarAr (350-400 μCi; 0.66-0.77 
nmol). The coronal slices intersect the center of the tumor. (C) Simulated image-guided resection of the tumor 96 h after the injection of huA33-Dye800-TCO (and 
thus 48 h after the administration of 64Cu-Tz-SarAr). From left to right: intact mouse, mouse after removal of the skin (blue arrow) covering the tumor, and mouse 
after excision of the tumor (white arrow). 
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PET and surgery. Along these lines, we are currently 
working to develop pretargeted PET/NIRF imaging 
systems that leverage the Al18F-labeled tetrazine 
radioligands that our laboratories have recently 
reported as well as a series of novel 68Ga-labeled 
tetrazines. Ultimately, it is our sincere hope that this 
new multimodal imaging technology will have a 
significant impact on both the staging and surgical 
intervention of patients with colorectal carcinoma.  
Supplementary Material  
Supplementary tables and figures.  
http://www.thno.org/v06p2267s1.pdf   
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